Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab versus standard care after myocardial infarction undergoing PCI
2021-000573-80Phase 4Active
- Sponsor
- Direction de la Recherche Clinique et de l'Innovation
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in myocardial infarction (MI) and dyslipidemia comparing Evolocumab arm with Standard of care arm (2 arms). Primary endpoint: Achievement of LDL-C reduction and target at 12 months. Started Mar 2021; status: active.
02
Drugs
evolocumab
03
Conditions
myocardial infarction (MI)dyslipidemia
Beyond the preview
Go deeper on 2021-000573-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000573-80.